Every 8-K that Maravai LifeSciences Holdings, Inc. (MRVI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MRVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRVI filings page.
Maravai LifeSciences Holdings, Inc. reported second quarter 2026 revenue of $51.4 million, up 8.5% year over year, with TriLink growing 11.5% and Cygnus up 2.8%. Net loss narrowed to $(21.6) million from $(69.8) million, and Adjusted EBITDA improved to $8.7 million from $(10.4) million.
For the six months ended June 30, 2026, total revenue increased 24.4%, driven by TriLink’s 37.3% growth, including $14.3 million of high‑volume CleanCap orders, while Cygnus grew 2.1%. Six‑month net loss was $(28.0) million versus $(122.7) million, and Adjusted EBITDA rose to $29.0 million from $(21.0) million.
The company reiterated full‑year 2026 revenue guidance of $205.0–$215.0 million and raised Adjusted EBITDA guidance to $33.0–$35.0 million from $30.0–$32.0 million. Management highlighted a new GMP enzyme manufacturing facility and continued adoption of the ModTail™ product line, now with more than 125 active customers.
Maravai LifeSciences refinanced its main credit facilities through a new $150 million term loan and a $30 million revolving credit facility maturing on June 2, 2032. Subsidiaries Maravai Intermediate Holdings and Maravai Topco entered into the new credit agreement with a lender group.
Proceeds from the new term loan, plus about $98.5 million of cash on hand, were used to fully repay and terminate the prior credit agreement that was due in October 2027. The transaction reduces long-term debt from roughly $242.9 million of aggregate principal to $150.0 million and extends the company’s debt maturity profile.
Borrowings bear interest at Term SOFR plus 5.00% per annum, with a potential 0.25% stepdown tied to leverage, and carry customary covenants and events of default, including a financial covenant based on a consolidated first lien net leverage ratio.
Maravai LifeSciences Holdings, Inc. reported the results of its 2026 Annual Meeting of Shareholders. As of the March 27, 2026 record date, the company had 258,180,170 shares of common stock outstanding, including 147,496,090 Class A shares and 110,684,080 Class B shares.
Shareholders holding 236,082,968 shares were present in person or by proxy, establishing a quorum. Three directors — Bernd Brust, Gregory T. Lucier and Luke Marker — were elected to three-year terms ending at the 2029 Annual Meeting. Shareholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved on a non-binding advisory basis the compensation of the named executive officers.
Maravai LifeSciences Holdings, Inc. reported much stronger results for the first quarter ended March 31, 2026. Revenue rose to $65.8 million, up 40.5% from the prior-year period, driven mainly by TriLink, which delivered $47.5 million of revenue, including $14.3 million from high-volume CleanCap orders for commercial COVID-19 vaccine programs.
The company posted a net loss of $6.4 million, a sharp improvement from a $52.9 million loss a year earlier, as gross profit expanded and operating expenses declined without the prior goodwill impairment. Adjusted EBITDA turned positive to $20.3 million from a loss of $10.5 million, and free cash flow improved to $4.2 million from negative $13.9 million, indicating better cash generation.
On the back of this performance, Maravai raised its full-year 2026 guidance, now expecting revenue between $205.0 million and $215.0 million and Adjusted EBITDA between $30.0 million and $32.0 million, compared with prior ranges of $200.0–$210.0 million and $18.0–$20.0 million. Management highlighted improving demand in its core TriLink base, non-COVID business and ongoing cost and efficiency initiatives.
Maravai LifeSciences reported fourth-quarter and full-year 2025 results showing lower revenue but improved profitability metrics in late 2025. Q4 2025 revenue was $49.9 million, down 11.8% year over year, with a net loss of $63.0 million and slightly positive Adjusted EBITDA of $0.5 million. Full-year 2025 revenue was $185.7 million, down 28.3%, with a net loss of $230.8 million and Adjusted EBITDA of $(31.2) million. TriLink revenue fell sharply due to fewer high-volume CleanCap vaccine orders, while Cygnus revenue grew modestly. For 2026, the company guides to revenue of $200–$210 million and Adjusted EBITDA of $18–$20 million, reflecting expectations for renewed growth and better margins.
Maravai LifeSciences Holdings, Inc. furnished an Item 2.02 report stating it issued a press release announcing financial results for the third quarter of 2025. The press release is included as Exhibit 99.1. The company states this information is furnished, not filed, under the Exchange Act and is not incorporated by reference unless expressly specified.
Maravai LifeSciences (MRVI) announced that three directors—Benjamin Daverman, Jessica Hopfield, PhD, and Murali Prahalad, PhD—voluntarily resigned effective October 21, 2025 as part of efforts to rationalize its Board size and reduce administrative costs. The Board will shrink from 11 to 8 directors effective October 27, 2025, and the company noted the departures were not due to any disagreement with management or the Board.
Following the changes, R. Andrew Eckert was appointed chair of the Nominating, Governance and Risk Committee and joined the Audit Committee, while Gregory T. Lucier joined the Nominating, Governance and Risk Committee. The Board also accelerated the vesting of all unvested restricted stock unit awards held by the departing directors as of the effective date.
Maravai LifeSciences announced a corporate restructuring to reduce operating costs, including a workforce reduction that management committed to on August 8, 2025. The company expects the reduction to affect approximately 25% of its workforce and estimates restructuring and related costs of $8.0 million to $9.0 million, primarily for severance and benefits, with the majority expected to be recognized in the second half of 2025. The company cautions the estimate is based on current assumptions and actual amounts may differ or include additional costs.
The Board eliminated two executive roles on August 7, 2025, resulting in the planned departures of Rebecca Buzzeo, Executive VP and Chief Commercial Officer, and Pete Leddy, Ph.D., Executive VP and Chief Administrative Officer, with expected last days of employment in September and October 2025. Their termination is treated as without "cause" under their agreements, and severance amounts are included in the estimated restructuring costs, subject to execution of separation agreements and releases. The press release with second-quarter results is furnished as Exhibit 99.1.
Maravai LifeSciences Holdings, Inc. (MRVI) filed an 8-K announcing a Chief Financial Officer transition effective 30 June 2025. The Board appointed Rajesh Asarpota (age 58) as CFO, replacing Kevin Herde, who will remain through 31 January 2026 as a paid consultant to ensure continuity. No family relationships or related-party transactions were reported.
Compensation package: Mr. Asarpota will receive a $550,000 base salary, 70 % target cash bonus, and a $200,000 sign-on bonus (claw-back if he departs within one year without “good reason” or is terminated for “cause”). Equity awards granted on the effective date include (i) 333,333 non-qualified stock options, (ii) 500,000 restricted stock units, and (iii) 750,000 performance stock units tied to stock-price hurdles. Options and RSUs vest 1/3 after one year and monthly thereafter over three years; PSUs cliff-vest based on share-price performance measured before the third anniversary. Equity may accelerate under specified conditions.
Severance terms: On a Qualifying Termination the CFO receives (i) any earned prior bonus, (ii) pro-rated current-year bonus, (iii) one year of base salary plus target bonus paid over 12 months, and (iv) up to 12 months of subsidised health coverage. If termination occurs within 24 months after a change in control, cash severance doubles to two times salary plus bonus, is paid lump-sum, health coverage extends to 24 months, and unvested time-vesting equity fully vests.
Outgoing CFO Kevin Herde will receive benefits under his May 2023 employment agreement upon departure. A press release dated 25 June 2025 (Exhibit 99.1) announced the appointment; the release is furnished, not filed, under Regulation FD. An employment agreement (Exhibit 10.1) and customary indemnification agreement accompany the filing.